<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="109087">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01682564</url>
  </required_header>
  <id_info>
    <org_study_id>m106CHF11E</org_study_id>
    <nct_id>NCT01682564</nct_id>
  </id_info>
  <brief_title>To Evaluate the Efficacy and Safety on Blood Pressure In Patients With Hypertension Diagnosed Congestive Heart Failure</brief_title>
  <acronym>CANTABILE</acronym>
  <official_title>Open Label, Randomized, Active Drug Comparative, Parallel Group, Multi-center, Phase IV Study to Compare and Evaluate the Efficacy and Safety of Candemore Tab and Atacand Tab.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare and evaluate the efficacy and safety of Candemore tab. versus Atacand tab. on
      blood pressure in patients with hypertension diagnosed congestive heart failure
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label, randomized, active drug comparative, Parallel group, Multi-center,
      phase IV study. Patients receive candemore tablet or atacand tablet. Initial dose is 4mg/day
      or 8mg/day. Every 2 weeks, patients take double dose if patients blood pressure is measured
      SBP ≥ 100mmHg and DBP &gt; 60mmHg. Maximum dose is 16mg/day.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Anticipated">July 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Mean sitting Systolic Blood Pressure</measure>
    <time_frame>After 12 weeks of treatment</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Sitting Diastolic Blood Pressure</measure>
    <time_frame>After 12 weeks of treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>echocardiography</measure>
    <time_frame>After 12 weeks of treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Left Ventricle Volume, Left Ventricle Ejection Fraction, E/E' ration, Peak TR velocity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Creatinine and Potssium level</measure>
    <time_frame>After 4 and 12 weeks of treatment</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA class</measure>
    <time_frame>After 12 weeks of treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hypertension</condition>
  <condition>Congestive Heart Failure</condition>
  <arm_group>
    <arm_group_label>Candemore tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Candemore tablet
Initial dose : 4mg/day if SBP&lt;140mmHg and/or DBP&lt;90mmHg, 8mg/day if SBP≥140mmHg and DBP≥90mmHg
dose escalation : double dose if SBP≥100mmHg and DBP&gt;60mmHg (maximum dose 16mg/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atacand tablet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atacand tablet
Initial dose : 4mg/day if SBP&lt;140mmHg and/or DBP&lt;90mmHg, 8mg/day if SBP≥140mmHg and DBP≥90mmHg
dose escalation : double dose if SBP≥100mmHg and DBP&gt;60mmHg (maximum dose 16mg/day)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candemore tablet</intervention_name>
    <description>Initial dose : 4mg/day if SBP&lt;140mmHg and/or DBP&lt;90mmHg, 8mg/day if SBP≥140mmHg and DBP≥90mmHg
dose escalation : double dose if SBP≥100mmHg and DBP&gt;60mmHg (maximum dose 16mg/day)</description>
    <arm_group_label>Candemore tablet</arm_group_label>
    <other_name>Candemore tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atacand tablet</intervention_name>
    <description>Initial dose : 4mg/day if SBP&lt;140mmHg and/or DBP&lt;90mmHg, 8mg/day if SBP≥140mmHg and DBP≥90mmHg
dose escalation : double dose if SBP≥100mmHg and DBP&gt;60mmHg (maximum dose 16mg/day)</description>
    <arm_group_label>Atacand tablet</arm_group_label>
    <other_name>Atacand tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  willing and able to provide written informed consent

          -  age 20 years or older

          -  patient with congestive heart failure, taking treatment medicine and NYHA grade
             II~III

          -  patient with hypertension, taking treatment medicine or SBP ≥ 140mmHg or DBP ≥ 90mmHg
             at the screening visit

        Exclusion Criteria:

          -  Known or suspected secondary hypertension(ex. aortic coactation, primary
             hyperaldosteronism, renal artery stenosis, pheochromocytoma, cushing syndrome,
             polycystic renal disease)

          -  blood creatinine level ≥ 2.5mg/dl

          -  blood potassium level &gt; 5.5mEq/L

          -  blood SGOT, SGPT level ≥ maximum normal range X3 or patient with sever hepatic
             dysfunction, cholestasis

          -  pregnant or breast-feeding

          -  premenopausal women not using adequate contraception

          -  patient has history about hypersensitivity or taboo of investigational product

          -  patient with lactose intolerance or Lapp lactase deficiency or glucode-galactose
             malabsorption

          -  administration of other study drugs within 1 month prior to screening

          -  history of ischemic heart disease(ex. angina pectoris, myocardial infarction) within
             the last 3 months

          -  in investigator's judgement
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>KeeSik Kim, M.D Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Daegu Catholic University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>KeeSik Kim, M.D Ph.D.</last_name>
    <phone>+82-53-650-3010</phone>
    <email>kks7379@cu.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Inje university pusan hospital</name>
      <address>
        <city>Busan</city>
        <state>Busanjin-gu Gaegum-dong</state>
        <zip>614-735</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong-Soo Kim, M.D Ph.D</last_name>
      <phone>+82-51-890-6039</phone>
      <email>dongskim@inje.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Dong-Soo Kim, M.D Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gyeongsang national university hospital</name>
      <address>
        <city>Jinju</city>
        <state>Chiram-dong</state>
        <zip>660-702</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Choong Hwan Kwak, M.D</last_name>
      <phone>+82-10-8503-9755</phone>
      <email>cwakch@naver.com</email>
    </contact>
    <investigator>
      <last_name>Choong Hwan Kwak, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Daegu fatima hospital</name>
      <address>
        <city>Daegu</city>
        <state>Dong-gu Sinam-dong</state>
        <zip>701-724</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Byung-Chun Jung, M.D Ph.D</last_name>
      <phone>+82-53-940-7293</phone>
      <email>augustjbc@yahoo.co.kr</email>
    </contact>
    <investigator>
      <last_name>Byung-Chun Jung, M.D Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Daedong hospital</name>
      <address>
        <city>Busan</city>
        <state>Dongnae-gu Myeongnyun-dong</state>
        <zip>607-711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Byung Soo Kim, M.D Ph.D</last_name>
      <phone>+82-51-741-5083</phone>
      <email>kbsmd@unitel.co.kr</email>
    </contact>
    <investigator>
      <last_name>Byung Soo Kim, M.D Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inje university haeundae paik hospital</name>
      <address>
        <city>Busan</city>
        <state>Haeundae-gu Heaundae-ro 875</state>
        <zip>612-030</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Doo-il Kim, M.D Ph.D</last_name>
      <phone>+82-51-797-3050</phone>
      <email>jo1216@chollian.net</email>
    </contact>
    <investigator>
      <last_name>Doo-il Kim, M.D Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maryknoll medical center</name>
      <address>
        <city>Busan</city>
        <state>Jung-gu Daecheong-dong</state>
        <zip>600-730</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tae Ik Kim, M.D</last_name>
      <phone>+82-51-461-2429</phone>
      <email>kimti2429@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Tae Ik Kim, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Keimyung university dongsan medical center</name>
      <address>
        <city>Daegu</city>
        <state>Jung-gu Dongsan-dong</state>
        <zip>700-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyungseop Kim, M.D</last_name>
      <phone>+82-10-9351-938</phone>
      <email>khyungseop@dsmc.or.kr</email>
    </contact>
    <investigator>
      <last_name>Hungseop Kim, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kyungpook national university hospital</name>
      <address>
        <city>Daegu</city>
        <state>Jung-gu Samdeok-dong</state>
        <zip>700-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong Hun Yang, M.D Ph.D</last_name>
      <phone>+82-10-3005-7547</phone>
      <email>ddhyang@knu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Dong Hun Yang, M.D Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samsung changwon hospital</name>
      <address>
        <city>Changwon</city>
        <state>Masanhoiwon-gu Hapseong-dong 50</state>
        <zip>630-723</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juhyeon Oh, M.D Ph.D</last_name>
      <phone>+82-55-290-6054</phone>
      <email>ojh@korea.com</email>
    </contact>
    <investigator>
      <last_name>Juhyeon Oh, M.D Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yeungnam university medical center</name>
      <address>
        <city>Daegu</city>
        <state>Nam-gu Daemyeong-dong</state>
        <zip>705-717</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong Gu Shin, M.D Ph.D</last_name>
      <phone>+82-10-4761-9123</phone>
      <email>dgshin@med.yu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Dong Gu Shin, M.D Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Daegu catholic univ. medical center</name>
      <address>
        <city>Daegu</city>
        <state>Nam-gu Daemyung-dong</state>
        <zip>705-718</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>KeeSik Kim, M.D Ph.D</last_name>
      <phone>+82-53-650-3010</phone>
      <email>kks7379@cu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>KeeSik Kim, M.D Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kosin university gospel hospital</name>
      <address>
        <city>Busan</city>
        <state>Seo-gu Amnam-dong</state>
        <zip>602-702</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tae-joon Cha, M.D Ph.D</last_name>
      <phone>+82-51-990-6725</phone>
      <email>chatjn@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Tae-joon Cha, M.D Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dong-A university medical center</name>
      <address>
        <city>Busan</city>
        <state>Seo-gu Dongdaesin-dong</state>
        <zip>602-715</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tae Ho Park, M.D Ph.D</last_name>
      <phone>+82-51-240-2964</phone>
      <email>thpark@dau.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Tae Ho Park, M.D Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dongguk university gyeongju hospital</name>
      <address>
        <city>Gyeongju</city>
        <state>Seokjang-dong</state>
        <zip>780-350</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deuk-Young Nah, M.D</last_name>
      <phone>+82-54-770-8561</phone>
      <email>ptca@dongguk.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Deuk-Young Nah, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <lastchanged_date>September 6, 2012</lastchanged_date>
  <firstreceived_date>September 4, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Candemore</keyword>
  <keyword>Atacand</keyword>
  <keyword>Candesartan cilexetil</keyword>
  <keyword>Primary Hypertension</keyword>
  <keyword>Congestive Hypertension</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Candesartan cilexetil</mesh_term>
    <mesh_term>Candesartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
